|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | Prescribing Pattern of Drugs Used in Adult Chronic Liver Disease Patients with Co-morbid Conditions and Assessment of Severity using MELD Score: A Cross-Sectional Study in A Tertiary Care Hospital in Mandya |
| Authors Name: | PRATHIKSHA K. M , J ANDREWS GNANAPRAKASAM , RIYA SARA THOMAS , SADIYA SAMREEN , DR. DIVYASHREE N |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_208771
|
| Published Paper Id: | IJNRD2311150 |
| Published In: | Volume 8 Issue 11, November-2023 |
| DOI: | |
| Abstract: | Chronic liver disease (CLD) causes the liver's function to gradually deteriorate. Although comorbidities are neither causes nor effects of CLD, they may have an impact on mortality, making them clinically relevant. The most frequently prescribed medication for CLD can be found by identifying prescribing trends, which aids in finding the ideal treatment plan. The evaluation of the disease's severity contributes to the development of methods for halting disease progression and avoiding new consequences. Our aim is to describe the prescribing pattern of drugs used in adult chronic liver disease patients with co-morbid conditions and also to describe the severity of these patients using the Model for End-Stage Liver Disease (MELD) Score. A cross-sectional study on 132 cases of chronic liver disease was conducted at the Department of General Medicine, MIMS Mandya. All the data related to this study was collected from the case sheet, lab reports, treatment chart, and interviews with the patient or patient caretaker using a pretested, semi-structured proforma. The final result was determined using basic statistical analysis. Among the study population of 132 patients, 85% were male and 15% were female. The most common aetiology of the disease was alcoholism (91%). The most affected age group was 38–47 years old. Anaemia, hypertension, and diabetes mellitus were the most commonly observed comorbidities in CLD patients, which demands a multidisciplinary approach to ensure the best possible outcomes for patients. Most prescribed drugs were hepatoprotective, antibiotics, vitamin supplements, and diuretics. The MELD score of the majority of the population was between 20 and 29 and had a mortality probability of 19.6%. In our study, we assessed drug usage patterns, co-morbidity patterns, and the severity of disease in CLD patients with comorbid conditions. Through our research and analysis, several key findings have emerged. (a). Polypharmacy: Patients with CLD and comorbid conditions often require multiple medications to manage their health. The complexity of drug regimens can lead to challenges in adherence and potential drug-drug interactions. (b). Medication selection: Prescribing decisions in this patient’s population must carefully consider the potential impact of drugs on liver disease. It requires a delicate balance between managing co-morbidities and minimising hepatotoxicity. (c). Individualised treatment: There is no one-size-fits-all approach to drug prescribing for CLD patients with comorbidities. Tailoring treatment to each patient’s specific condition, liver function, and co-existing diseases is essential. (d). MELD scores can enable healthcare providers to identify patients at higher risk of adverse outcomes, facilitating early intervention. |
| Keywords: | Chronic liver disease, Co-morbidities, MELD score, Prognosis, Mortality. |
| Cite Article: | "Prescribing Pattern of Drugs Used in Adult Chronic Liver Disease Patients with Co-morbid Conditions and Assessment of Severity using MELD Score: A Cross-Sectional Study in A Tertiary Care Hospital in Mandya", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 11, page no.b384-b390, November-2023, Available :http://www.ijnrd.org/papers/IJNRD2311150.pdf |
| Downloads: | 000118752 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2311150 Registration ID: 208771 Published In: Volume 8 Issue 11, November-2023 DOI (Digital Object Identifier): Page No: b384-b390 Country: MANDYA, KARNATAKA, INDIA Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2311150 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2311150 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn